Anthrax vaccine. Model of a response to the biologic warfare threat

Infectious Disease Clinics of North America

Volumn 13, Issue 1, 1999, Pages 187-208

  Nass, M ^a  

^a Parkview Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE;

ANTHRAX; BIOLOGICAL WARFARE; DRUG SAFETY; MEDICAL ETHICS; REVIEW; SOLDIER; VACCINATION;

EID: 0032932989     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70050-7     Document Type: Article

References (102)

1. T.I. Anaisimova T.V. Pimenov V.V. Kozhukhov Development of method for preparation and maintenance of the anthrax strain STI-1 and test strain Zenkovsky Salisbury Medical Bulletin 87 suppl 1996 122
2. G. Annas Changing the consent rules for Desert Storm N Engl J Med 326 1992 770
3. B.F. Anthony A. Sutton The role of the FDA in vaccine testing and licensure Lelvine M.M. Woodrow G.C. Kaper J.B. New Generation Vaccines ed 2 1997 Marcel Dekker New York 1185
4. Anthrax vaccine is refused. Washington Post. April 9, 1998, A5
5. B.J. Bernstein The birth of the US biological warfare program Sci Am 256 1987 116
6. B.J. Bernstein Churchill's secret biological weapons Bull At Sci 43 1987 46
7. P.S. Brachman A.M. Friedlander Anthrax Plotkin S.A. Mortimer E.A. Vaccines ed 2 1994 WB Saunders Philadelphia 729
8. P.S. Brachman H. Gold S.A. Plotkin Field evaluation of a human anthrax vaccine Am J Public Health 52 1962 632
9. Broad W: Gene-engineered anthrax: Is it a weapon? New York Times, Feb 14, 1998
10. Broad W: Norway's 1918 lump of sugar yields clues on anthrax in war. New York Times June 25, 1998, A11
11. M.G. Broster S.E. Hibbs Protective efficacy of anthrax vaccines against aerosol challenge Salisbury Medical Bulletin 68 Suppl 1990 91
12. Burrow GN: Letter to Rudy de Leon, Undersecretary for Defense. 2/19/98 http://www.defenselink.mil/other_info/burrows.html
13. J.L. Bussiere G.C. McCormick J.D. Green Preclinical safety assessment considerations Pharm Biotechnol 6 1995 61
14. D. Butler Admission on Gulf War vaccines spurs debate on medical records Nature 390 1997 3
15. Committee on Government Reform and Oversight Gulf War veterans' illnesses: VA, DOD continue to resist strong evidence linking toxic causes to chronic health effects 1997 US Government Printing Office Washington, DC HR105 HR388
16. Committee on Veterans' Affairs, Staff Report, US Senate: Is military research hazardous to veterans' health? Lessons spanning half a century. S. Prt. 103-97, December 8, 1994
17. N.M. Coulson M. Fulop R.W. Titball Bacillus anthracis protective antigen, expressed in Salmonella typhimurium SL 3261, affords protection against anthrax spore challenge Vaccine 12 1994 1395
18. S.L. Dong Progress in the control and research of anthrax in China Salisbury Medical Bulletin 68 suppl 1990 104
19. N.S. Duesbury C.P. Webb S.H. Leppla Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor Science 280 1998 734
20. J.W. Ezzell T.G. Abshire Immunological analysis of cell-associated antigens of Bacillus anthracis Infect Immun 56 1988 349
21. J.W. Farchaus W.J. Ribot S. Jendrek Fermentation, purification, and characterization of protective antigen from a recombinant, avirulent strain of Bacillus anthracis Appl Environ Microbiol 64 1998 982
22. W.E. Farrar Virulence and vaccines Ann Intern Med 121 1994 379
23. Food and Drug Administration: Report of the Inspection of Michigan Biologic Products Institute (Form FDA 483). February 20, 1998
24. Fouet A. Sirard J.-C. M. Mock Virulence gene determinants Salisbury Medical Bulletin 87 suppl 1996 84
25. Fox J: ASM News. May, 1998, p 255
26. A.M. Friedlander S.L. Welkos M.L.M. Pitt Postexposure prophylaxis against experimental inhalation anthrax J Infect Dis 167 1993 1239
27. G.L. Geison The private science of Louis Pasteur 1995 Princeton University Press Princeton, NJ
28. E. Geissler Biological and Toxin Weapons Today 1986 Stockholm International Peace Research Institute, Oxford University Press Oxford
29. Ginburg Y: Sailors refuse vaccine. Navy Times April 20, 1998
30. H. Gold Studies on anthrax J Lab Clin Med 21 1935 134
31. P. Hambleton P.C.B. Turnbull Anthrax vaccine development: A continuing story Adv Biotechnol Processes 13 1990 105
32. R.H. Heeren Anthrax in Louisiana New Orleans Medical and Surgical Journal 99 1947 545
33. R.K. Holmes Anthrax Fauci A.S. Braunwald E. Isselbacher K.J. Harrison's Principles of Internal Medicine ed 14 1998 McGraw-Hill New York 897
34. D.L. Huxsoll W.C. Patrick C.D. Parrott Veterinary services in biological disasters J Am Vet Med Assn 190 1987 714
35. Ivins BE: Anthrax vaccines –– how stable is the potency? Presented at the ASM 98th General Meeting, Atlanta, May 18, 1998
36. B.E. Ivins J.W. Ezzell J. Jemski Immunization studies with attenuated strains of Bacillus anthracis Infect Immun 52 1986 454
37. B.E. Ivins P.F. Fellows G.O. Nelson Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea pigs Vaccine 12 1994 872
38. B.E. Ivins P.F. Fellows M.L.M. Pitt Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys Salisbury Medical Bulletin 87 suppl 1996 125
39. B.E. Ivins P. Fellows L. Pitt Experimental anthrax vaccines: Efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs Vaccine 13 1995 1779
40. B.E. Ivins S.L. Welkos Recent advances in the development of an improved, human anthrax vaccine Eur J Epidemiol 4 1988 12
41. B.E. Ivins S.L. Welkos G.B. Knudson Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen Infect Immun 58 1990 303
42. B.E. Ivins S.L. Welkos S.F. Little Cloned protective activity and progress in development of improved anthrax vaccines Salisbury Medical Bulletin, 68 suppl 1990 86
43. B.E. Ivins S.L. Welkos S.F. Little Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants Infect Immun 60 1992 662
44. P. Jackson M.E. Hugh-Jones D.M. Adair PCR analysis of tissue samples from the 1979 Sverdlovsk anthrax victims: The presence of multiple Bacillus anthracis strains in different victims Proc Natl Acad Sci U S A 95 1998 1224
45. Joint Vaccine Acquisition Program Final Programmatic Environmental Assessment August 1997 Joint Vaccine Acquisition Program Project Management Office, Department of the Army
46. M.N. Jones R.J. Beedham P.C.B. Turnbull Antibiotic prophylaxis for inhalation anthrax Salisbury Medical Bulletin 87 suppl 1996 127
47. M.N. Jones R.J. Beedham P.C.B. Turnbull Efficacy of the UK human anthrax vaccine in guinea pigs against aerosolized spores of Bacillus anthracis Salisbury Medical Bulletin 87 suppl 1996 123
48. R.P. Kadlec A.P. Zelicoff A.M. Vrtis Biological weapons: Control, prospects and implications for the future JAMA 278 1997 351
49. Kaufman A: Anthrax Vaccine Safety and Efficacy. ProMED-Mail, April 16, 1998. http://www.healthnet.org/programs/promed-hma/9804/msg00104.html
50. G.B. Knudsen Treatment of anthrax in man: History and current concepts Mil Med 151 1986 71
51. S.H. Leppla A.F. Friedlander Y. Singh A model for anthrax toxic action at the cellular level Salisbury Medical Bulletin 68 suppl 1990 41
52. S.H. Leppla K.R. Klimpel Y. Singh Interaction of anthrax toxin with mammalian cells Salisbury Medical Bulletin 87 suppl 1996 91
53. O.T. Lesnyak R.A. Saltykov Comparative assessment of anthrax vaccine strains Zh Mikrobiol Epidemiol Immunobiol 47 1970 32
54. R.E. Lincoln J.S. Walker F. Klein Value of field data for extrapolation in anthrax Fed Proc 26 1967 1558
55. S.F. Little B.E. Ivins P.F. Fellows Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs Infect Immun 65 1997 5171
56. S.F. Little G.B. Knudsen Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig Infect Immun 52 1986 509
57. Miller C: Reserve troops suffering from syndrome. PA News (UK) September 24, 1997
58. Miller J: Clinton seeks additional $300 million to fight bioterrorism. New York Times June 9, 1998, A16
59. Miller J: Company led by top admiral buys Michigan vaccine lab. New York Times July 8, 1998
60. M. Nass Anthrax epizootic in Zimbabwe, 1978–1980: Due to deliberate spread? Physicians for Social Responsibility Quarterly 2 1992 198
61. M. Nass Anthrax vaccine and the prevention of biological warfare ASA Newsletter #65 1998 1 20
62. Nass M: Anthrax Vaccine Safety and Efficacy: Response to Army Surgeon General Ronald Blanck's posting. Pro-MED Mail, May 7, 1998. http://www.healthnet.org/programs/promed-hma/9805/msg00044.html
63. M. Nass The labyrinth of biological defense PSR Quarterly 1 1991 24
64. M.J. Newman M.F. Powell Immunological and formulation design considerations for subunit vaccines Pharm Biotechnol 6 1995 1
65. Norton-Taylor R: MOD ignored warning on Gulf drugs. The Guardian (UK) October 29, 1997
66. OraVax Joins DynPort in Department of Defense Contract to Develop FDA-Licensed Vaccines Against Potential Biological Warfare Agents. Cambridge, Mass., May 04/98 PRNewswire/ –– OraVax
67. W.A. Orenstein A.R. Hinman K.J. Bart Immunization Mandell G.L. Bennett J.E. Dolin R. Principles and Practice of Infectious Diseases ed 4 1995 Churchill Livingstone NY 2770
68. M.L.M. Pitt B.E. Ivins J.E. Estep Comparison of the efficacy of purified protective antigen and MDPH to protect non-human primates from inhalation anthrax Salisbury Medical Bulletin 87 suppl 1996 130
69. A.P. Pomerantsev Y.U.V. Mockov L.I. Marinin Anthrax prophylaxis by antibiotic resistant strain STI––AR in combination with urgent antibiotic therapy Salisbury Medical Bulletin 87 suppl 1996 131
70. A.P. Pomerantsev N.A. Staritsin Y.V. Mockov L.I. Marinin Expression of cereolysin AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection Vaccine 15 1997 1846
71. Presidential Advisory Committee on Gulf War Veterans' Illnesses Interim Report February 1996 US Govt Printing Office Wash., DC
72. Presidential Advisory Committee on Gulf War Veterans' Illnesses Special Report October 31, 1997 US Govt Printing Office Wash., DC
73. Preston R: The Bioweaponeers. New Yorker, March 9, 1998, p 52
74. M. Puziss L.C. Manning J.W. Lynch Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures Appl Microbiol 11 1963 330
75. J.C. Regan The local and general serum treatment of cutaneous anthrax JAMA 77 1921 1944
76. Rodriguez PM: Anti-HIV mix is found in blood of Gulf War veterans. Washington Times, August 24, 1997
77. G. Rook A. Zumla Gulf War syndrome: Is it due to a systemic shift in cytokine balance towards a Th2 profile? Lancet 349 1997 1831
78. A.S. Schlingman H.B. Devlin G.C. Wright Immunizing activity of alum-precipitated protective antigen of Bacillus anthracis in cattle, sheep and swine Am J Vet Res 17 1956 256
79. E. Shlyakov Anthraxin—a skin test for early and retrospective diagnosis of anthrax and anthrax vaccination assessment Salisbury Medical Bulletin 87 suppl 1996 109
80. E.N. Shlyakov E. Rubinstein Human live anthrax vaccine in the former USSR Vaccine 12 1994 727
81. E. Shlyakov E. Rubinstein I. Novikov Anthrax post-vaccinal cell-mediated immunity in humans: Kinetics pattern Vaccine 15 1997 631
82. A.S. Stepanov K.R. Klimpel S.H. Leppla Extracellular proteases in Bacillus anthracis Salisbury Medical Bulletin 87 suppl 1996 87
83. A.S. Stepanov S.H. Leppla Macrophages are killed by the plasmid and chromosomally encoded factors synthesized by Bacillus anthracis inside and outside the host cell Salisbury Medical Bulletin 87 suppl 1996 89
84. A.V. Stepanov L.I. Marinin A.P. Pomerantsev Development of novel vaccines against anthrax in man J Biotech 44 1996 155
85. A.S. Stepanov L.I. Marinin N.A. Staritsyn Molecular mechanisms underlying Bacillus anthracis infection at early stages and search for novel vaccines Vestn Ross Akad Med Nauk 6 1997 16
86. A.S. Stepanov N.I. Mikshis M.F. Bolotnikova Role of chromosomally-encoded factors in virulence of Bacillus anthracis for mice and guinea pigs Salisbury Medical Bulletin 87 suppl 1996 86
87. P.C.B. Turnbull S.H. Leppla M.G. Broster Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity Med Microbiol Immunol 177 1988 293
88. P.C.B. Turnbull Anthrax vaccines: Past, present and future Vaccine 9 1991 533
89. P.C.B. Turnbull M.G. Broster J.A. Carman Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity Infect Immun 52 1986 356
90. P.C.B. Turnbull C.P. Quinn P. Hewson Protection conferred by microbially supplemented UK and purified PA vaccines Salisbury Medical Bulletin 68 suppl 1990 89
91. Van Ness G.B. Ecology of anthrax Science 172 1972 1303
92. J.A. Vick R.E. Lincoln F. Klein Neurological and physiological responses of the primate to anthrax toxin J Infect Dis 118 1968 85
93. F.R. Vogel M.F. Powell Compendium of vaccine adjuvants and excipients Powell M.F. Newman M.J. Vaccine Design: The Subunit and Adjuvant Approach 1995 Plenum Press New York 1464
94. S. Welkos D. Becker A.F. Friedlander Pathogenesis and host resistance to Bacillus anthracis: A mouse model Salisbury Medical Bulletin 68 suppl 1990 49
95. S.L. Welkos A.M. Friedlander Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice Microb Pathog 5 1988 127
96. S.L. Welkos A.M. Friedlander Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis Microb Pathog 4 1988 53
97. H.W. Whitford Incidence of anthrax in the USA: 1945–1988 Salisbury Medical Bulletin 68 suppl 1990 5
98. P. Williams D. Wallace Unit 731: Japan's Secret Biological Warfare in World War II 1989 The Free Press New York
99. E.D. Williamson D.A. Percival N.J. Frith Cell-mediated immune response to the toxins of anthrax Salisbury Medical Bulletin 68 suppl 1990 92
100. R.A. Zilinskas Iraq's biological weapons JAMA 278 1997 418
101. Zoon KC: Letter from the Director of the FDA Center for Biologics Evaluation and Research to Robert Myers, Responsible Head, Michigan Biologic Products Institute. Available: http:www.dallasnw.quik.com/cyberella/Anthrax/Zoon4_98.htm March 11, 1997
102. Zoon KC: Letter to Patrick Eddington. FDA via FOIA. Available: http://www.dallasnw.quik. com/cyberella/Anthrax/Mar97.htm April 28, 1998